cash flow reconciliationreview2023-12-31
Operating, investing and financing flows differ from the reported change in cash by 20794000, beyond tolerance 1000000.
Revenue
Unavailable
Fiscal year ended 2025-12-31Operating income
Unavailable
Fiscal year ended 2025-12-31Free cash flow
Unavailable
Fiscal year ended 2025-12-31This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Q32 Bio Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Unavailable | $0 | $0 | $0 | $0 | -$14.66M | $1.86M | $3.20M | $2.95M | $802.00K |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | Unavailable | -$14.53M | -$18.81M | -$17.92M | -$14.84M | -$25.81M | -$7.80M | -$7.28M | -$7.37M | -$34.49M |
| Net income | Unavailable | -$14.19M | -$17.60M | -$16.98M | $1.03M | -$27.07M | -$14.03M | -$5.81M | -$6.84M | -$34.30M |
| Research & development | Unavailable | $10.54M | $14.35M | $13.41M | $9.84M | $8.34M | $7.46M | $8.02M | $7.91M | $27.15M |
| Weighted-average diluted shares | Unavailable | Unavailable | shares 12.08M | shares 11.96M | shares 2.33M | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Pretax income | Unavailable | -$14.17M | -$17.60M | -$15.53M | $1.20M | -$26.81M | -$13.97M | -$5.81M | -$6.84M | -$33.04M |
| Income tax expense | Unavailable | $21.00K | $0 | $0 | $0 | $383.00K | -$65.00K | $0 | $0 | $1.53M |
| Diluted EPS | Unavailable | Unavailable | $-1.46 | $-1.42 | $-6.33 | Unavailable | $-40.52 | $-16.69 | $-19.84 | Unavailable |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | Unavailable | $3.98M | $4.47M | $4.51M | $5.00M | $2.81M | $2.19M | $2.46M | $2.41M | $8.15M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $48.30M | $77.96M | $89.08M | $97.66M | $115.51M | $25.62M | $36.26M | $20.06M | $31.41M | $33.99M |
| Total assets | $61.78M | $92.33M | $104.54M | $124.21M | $152.33M | $47.06M | $140.06M | $169.34M | $197.88M | $228.47M |
| Current assets | $55.05M | $81.88M | $93.90M | $111.62M | $138.04M | $28.72M | $106.64M | $131.34M | $153.58M | $181.02M |
| Total liabilities | $19.76M | $86.66M | $86.25M | $90.70M | $103.56M | $118.53M | $51.85M | $49.96M | $45.98M | $50.49M |
| Current liabilities | $11.35M | $16.46M | $14.38M | $17.19M | $32.95M | $14.11M | $25.29M | $22.94M | $18.51M | $22.58M |
| Total equity incl. NCI | $42.01M | $5.68M | $18.30M | $33.51M | $48.77M | -$182.92M | -$156.45M | -$142.72M | -$137.24M | -$130.71M |
| Temporary (mezzanine) equity | Unavailable | $0 | $0 | $0 | $0 | $111.44M | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts receivable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $879.00K | $2.99M | $1.26M | $2.48M | $4.96M | $3.47M | $7.80M | $3.39M | $3.64M | $1.14M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | Unavailable | -$11.43M | -$19.52M | -$22.21M | -$14.55M | -$10.72M | $15.90M | -$11.37M | -$12.50M | -$27.20M |
| Capital expenditures | Unavailable | $2.00K | $58.00K | $15.00K | $0 | $0 | $1.00K | -$1.00K | $5.00K | $9.00K |
| Investing cash flow | Unavailable | -$2.00K | $9.94M | $9.89M | $97.00K | $0 | -$1.00K | $1.00K | -$5.00K | $17.99M |
| Financing cash flow | Unavailable | $317.00K | $997.00K | -$5.52M | $99.35M | $76.00K | $300.00K | $15.00K | $15.00K | $32.00K |
| Net change in cash | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $10.16M | -$47.69M | $37.34M | $5.47M | -$9.18M |
| Stock-based compensation | Unavailable | $1.25M | $1.38M | $1.34M | $417.00K | $521.00K | $301.00K | $310.00K | $296.00K | $3.09M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | -$11.43M | -$19.58M | -$22.23M | Unavailable | -$10.72M | $15.90M | Unavailable | -$12.50M | -$27.21M |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | -419.5% | -227.0% | -250.2% | -4301.0% |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | 855.3% | Unavailable | -424.2% | -3392.5% |
| SBC / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | 16.2% | 9.7% | 10.0% | 385.2% |
| Current ratio | 4.85x | 4.97x | 6.53x | 6.49x | 4.19x | 2.04x | 4.22x | 5.73x | 8.30x | 8.02x |
| Revenue YoY growth | Unavailable | Unavailable | -100.0% | -100.0% | -100.0% | -1928.2% | 131.8% | 299.6% | 267.5% | 0.0% |
| Net margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | -754.8% | Unavailable | Unavailable | -4276.2% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | 401.5% | 250.1% | 268.4% | 3385.2% |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | 0.1% | -0.0% | 0.2% | 1.1% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | 0.0% | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open QTTB in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-10View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-08View SEC filing
Reconciliation checks needing review
8 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
cash flow reconciliationreview2023-09-30
Operating, investing and financing flows differ from the reported change in cash by 63886000, beyond tolerance 1000000.
balance equationreview2023-09-30
Difference 244662000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2023-06-30
Difference 262096000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
cash flow reconciliationreview2023-06-30
Operating, investing and financing flows differ from the reported change in cash by 48694000, beyond tolerance 1000000.
balance equationreview2023-03-31
Difference 289138000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
cash flow reconciliationreview2023-03-31
Operating, investing and financing flows differ from the reported change in cash by 17954000, beyond tolerance 1000000.
balance equationreview2022-12-31
Difference 308690000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.